Pasi A. Jänne, MD, PhD, on Osimertinib With and Without Chemotherapy for NSCLC: FLAURA2 Trial Update

Posted: Friday, June 28, 2024

Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, discusses an analysis from the FLAURA2 study, which suggests that osimertinib plus chemotherapy may correlate with improved outcomes vs osimertinib alone for some patients with non–small cell lung cancer (NSCLC).

---